2 completed, 1 recruiting, 1 unknown, 1 withdrawn. 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow C2N Diagnostics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease PrecivityAD2 - Early Testing, PrecivityAD2 - Delayed Testing - Alzheimers Disease | Not applicable | Withdrawn | C2N Diagnostics | 2025-07-01 | 2025-12-16 | |
| Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers Digital MoCA, XpressO, MoCA - Mild Cognitive Impairment, Alzheimer Disease | Recruiting | MoCA Clinic and Institute | 500 | 2025-03-14 | 2025-07-01 | |
| Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey PrecivityAD2(TM) blood test - Alzheimer Disease, Mild Cognitive Impairment | Unknown | C2N Diagnostics | 400 | 2023-11-15 | 2025-03-28 | |
| Quality Improvement PrecivityAD Clinician Survey (QUIP I) PrecivityAD blood test - Alzheimer Disease, Mild Cognitive Impairment | Completed | C2N Diagnostics | 366 | 2021-03-01 | 2025-02-20 | |
| Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Single dose C2N-8E12, Single dose placebo - Progressive Supranuclear Palsy | Phase 1 | Completed | C2N Diagnostics | 32 | 2015-07-01 | 2017-07-26 |
Alzheimer Disease (4) · Cognitive Dysfunction (4) · Dementia (4) · Memory Disorders (1) · Supranuclear Palsy, Progressive (1) · Tauopathies (1)
United States (3) · Canada (1)
Adam Boxer, MD, PhD (1) · Mark Monane, MD, MBA, AGSF (1) · Tim West, Ph.D (1) · Vice President, Neurology (1) · Ziad Nasreddine, MD (1)